David A. Siegel Cytom X Therapeutics, Inc. Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.21 - $5.13 $14,036 - $59,508	11,600 Added 7.9%	158,400 $193,000
Q1 2024 May 15, 2024	BUY	$1.41 - $2.74 $148,896 - $289,344	105,600 Added 256.31%	146,800 $320,000
Q4 2023 Feb 14, 2024	SELL	$1.07 - $1.55 $71,369 - $103,385	-66,700 Reduced 61.82%	41,200 $63,000
Q3 2023 Nov 14, 2023	SELL	$1.26 - $1.87 $153,090 - $227,205	-121,500 Reduced 52.96%	107,900 $139,000
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $404,247 - $550,464	-286,700 Reduced 55.55%	229,400 $394,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.88 $13,024 - $25,344	-8,800 Reduced 1.68%	516,100 $779,000
Q4 2022 Feb 14, 2023	SELL	$1.19 - $1.91 $2,975 - $4,775	-2,500 Reduced 0.47%	524,900 $839,000
Q3 2022 Nov 14, 2022	BUY	$1.23 - $1.97 $172,692 - $276,588	140,400 Added 36.28%	527,400 $765,000
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $59,211 - $111,843	38,700 Added 11.11%	387,000 $708,000
Q1 2022 May 16, 2022	BUY	$2.67 - $4.68 $391,689 - $686,556	146,700 Added 72.77%	348,300 $930,000
Q4 2021 Feb 14, 2022	BUY	$3.87 - $7.39 $1,548 - $2,956	400 Added 0.2%	201,600 $873,000
Q3 2021 Nov 15, 2021	SELL	$4.32 - $6.43 $725,328 - $1.08 Million	-167,900 Reduced 45.49%	201,200 $1.02 Million
Q2 2021 Aug 16, 2021	SELL	$6.33 - $9.91 $1.78 Million - $2.79 Million	-281,800 Reduced 43.29%	369,100 $2.34 Million
Q1 2021 May 17, 2021	SELL	$6.6 - $9.0 $277,200 - $378,000	-42,000 Reduced 6.06%	650,900 $5.03 Million
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $898,036 - $1.1 Million	138,800 Added 25.05%	692,900 $4.54 Million
Q3 2020 Nov 16, 2020	BUY	$6.55 - $8.83 $80,565 - $108,609	12,300 Added 2.27%	554,100 $3.69 Million
Q2 2020 Aug 14, 2020	BUY	$7.4 - $14.64 $400,340 - $792,024	54,100 Added 11.09%	541,800 $4.51 Million
Q1 2020 May 15, 2020	BUY	$3.61 - $8.6 $27,436 - $65,360	7,600 Added 1.58%	487,700 $3.74 Million
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $1.27 Million - $2.18 Million	245,200 Added 104.38%	480,100 $3.99 Million
Q3 2019 Nov 14, 2019	SELL	$7.38 - $12.25 $135,054 - $224,175	-18,300 Reduced 7.23%	234,900 $1.73 Million
Q2 2019 Aug 14, 2019	BUY	$9.35 - $11.41 $19,635 - $23,961	2,100 Added 0.84%	253,200 $2.84 Million
Q1 2019 May 15, 2019	SELL	$9.5 - $19.16 $28,500 - $57,480	-3,000 Reduced 1.18%	251,100 $2.7 Million
Q4 2018 Feb 14, 2019	SELL	$12.69 - $18.61 $137,052 - $200,988	-10,800 Reduced 4.08%	254,100 $3.84 Million
Q3 2018 Nov 14, 2018	SELL	$18.04 - $26.41 $165,968 - $242,972	-9,200 Reduced 3.36%	264,900 $4.9 Million
Q2 2018 Aug 14, 2018	BUY	$21.38 - $29.68 $1.82 Million - $2.53 Million	85,300 Added 45.18%	274,100 $6.27 Million
Q1 2018 May 15, 2018	BUY	$21.76 - $34.22 $1.45 Million - $2.28 Million	66,700 Added 54.63%	188,800 $5.37 Million
Q4 2017 Feb 14, 2018	BUY	$19.0 - $23.09 $1.31 Million - $1.6 Million	69,200 Added 130.81%	122,100 $2.58 Million
Q3 2017 Nov 14, 2017	BUY	$13.53 - $18.17 $715,737 - $961,193	52,900	52,900 $961,000

Others Institutions Holding CTMX

# of Institutions

Shares Held

50.7M

Call Options Held

112K

Put Options Held

8.3K

Tang Capital Management LLC San Diego, CA

7.81M
Shares

$8.28 Million
0.79% of portfolio
Bvf Inc San Francisco, CA

5.23M
Shares

$5.54 Million
0.2% of portfolio
Vanguard Group Inc Valley Forge, PA

5.16M
Shares

$5.47 Million
0.0% of portfolio
Janus Henderson Group PLC London, X0

4.81M
Shares

$5.1 Million
0.0% of portfolio
Acadian Asset Management LLC Boston, MA

3.1M
Shares

$3.29 Million
0.01% of portfolio

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $69.9M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account